COLL
Collegium Pharmaceutical, Inc.
COLL's fundamentals are mixed, but it looks expensive: trading at 25x earnings, above its usual 19x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
COLL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
COLL's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
COLL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.5x | $24.95 | — |
| Cheap | 13x | $12.57 | -50% |
| Fair | 19x | $19.08 | -24% |
| Current | 25x | $24.95 | — |
| Expensive | 34x | $33.57 | +35% |
Historical ranges are pointers, not guarantees.
COLL's PE is in its expensive range at 25x. On analysts' estimates for next year's earnings, today's price would be 3.5x, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
COLL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect COLL's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
COLL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.07 | +607% |
| Q3 2026 | $1.00 | -38% |
| Q2 2026 | $1.24 | +19% |
| Q1 2026 | $2.04 | +67% |
| Q4 2025 | $1.71 | -8.1% |
| Q3 2025 | $1.61 | -31% |
| Q2 2025 | $1.04 | -60% |
| Q1 2025 | $1.22 | -49% |
| Q4 2024 | $1.86 | +58% |
COLL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
COLL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $216.3M | +3.3% |
| Q2 2026 | $199.9M | +6.3% |
| Q1 2026 | $193.5M | +8.9% |
| Q4 2025 | $205.4M | +13% |
| Q3 2025 | $209.4M | +31% |
| Q2 2025 | $188M | +29% |
| Q1 2025 | $177.8M | +23% |
| Q4 2024 | $181.9M | +22% |
COLL's revenue has grown year over year for 18 quarters in a row: $216M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -16 points |
| Q2 2026 | 1.9% | -17 points |
| Q1 2026 | 16% | +3.8 points |
| Q4 2025 | 30% | +8.6 points |
| Q3 2025 | 30% | +7.8 points |
| Q2 2025 | 19% | -14 points |
| Q1 2025 | 12% | -22 points |
| Q4 2024 | 21% | -20 points |
COLL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over COLL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
COLL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $86.3M | +10% |
| Q2 2026 | $70.8M | -2.1% |
| Q1 2026 | $56.8M | +4.1% |
| Q4 2025 | $122.4M | +46% |
| Q3 2025 | $78.3M | +$87.5M |
| Q2 2025 | $72.4M | +7.8% |
| Q1 2025 | $54.6M | -11% |
| Q4 2024 | $84.1M | +15% |
COLL generated $336M in free cash flow over the past year, up 16% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over COLL on cash flow, with more consistent year-over-year improvement.
COLL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +6.7M shares |
| 1 year | -0.8% | -329K shares |
| 3 years | -7% | -2.9M shares |
| 5 years | +7.9% | +2.8M shares |
| Available history | +16% | +5.5M shares |
COLL has 39M diluted shares, down 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $25M |
| Q3 2024 | — |
| Q4 2023 | $25M |
| Q4 2022 | $7.6M |
| Q4 2021 | $32.3M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over COLL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
COLL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.6x | Very low |
COLL's net debt is less than a year of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
COLL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 25.6 | Neutral |
COLL's weekly RSI is 39 (neutral) and its Stochastic is 26 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
COLL PE vs Healthcare Sector
| Metric | COLL | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.5% below |
| PE % | 66 | 29 | 37 pts above |
COLL is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
COLL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.2 | 7.5% above |
| 20 week MA | $27.2 | 8.2% below |
| 50 week MA | $34.7 | 28% below |
| 100 week MA | $33.7 | 26% below |
| 200 week MA | $31.6 | 21% below |
COLL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
COLL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $18.6 | -12% |
| 2021 | $18.6 | $19.5 | +4.9% |
| 2022 | $19.5 | $23.0 | +18% |
| 2023 | $23.0 | $30.8 | +34% |
| 2024 | $30.8 | $29.1 | -5.4% |
| 2025 | $29.1 | $49.8 | +71% |
| 2026 YTD | $49.8 | $25.0 | -50% |
COLL is down 50% so far in 2026, after finishing higher in four of the previous six years.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over COLL on returns for 2026, with the stronger performance.